Cargando…

Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction

We aimed to assess the association between CA125 and the long-term risk of total acute heart failure (AHF) admissions in patients with an index hospitalization with AHF and preserved ejection fraction (HFpEF). We prospectively included 2369 patients between 2008 and 2019 in three centers. CA125 and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Miñana, Gema, de la Espriella, Rafael, Palau, Patricia, Llácer, Pau, Núñez, Eduardo, Santas, Enrique, Valero, Ernesto, Lorenzo, Miguel, Núñez, Gonzalo, Bodí, Vicente, Heredia, Raquel, Sanchis, Juan, Bayés-Genís, Antoni, Chorro, Francisco J., Núñez, Julio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8789924/ https://www.ncbi.nlm.nih.gov/pubmed/35079082 http://dx.doi.org/10.1038/s41598-022-05328-2

Ejemplares similares

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure
por: Bertomeu‐Gonzalez, Vicente, et al.
Publicado: (2020)

Sex‐Related Differences in Mortality Following Admission for Acute Heart Failure Across the Left Ventricular Ejection Fraction Spectrum
por: Santas, Enrique, et al.
Publicado: (2021)

Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Prognostic Value of the Interaction between Galectin-3 and Antigen Carbohydrate 125 in Acute Heart Failure
por: Núñez, Julio, et al.
Publicado: (2015)

Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction
por: Amiguet, Martina, et al.
Publicado: (2023)

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure
por: Núñez, Julio, et al.
Publicado: (2017)

Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study
por: Núñez, Julio, et al.
Publicado: (2016)

Venous Leg Compression for Tissue Decongestion in Patients With Worsening Congestive Heart Failure
por: Civera, Jose, et al.
Publicado: (2022)

Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis
por: Miñana, Gema, et al.
Publicado: (2022)

Short‐Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial‐IRON Trial
por: del Canto, Irene, et al.
Publicado: (2022)

Biomarkers to Improve Decision-making in Acute Heart Failure
por: de la Espriella, Rafael, et al.
Publicado: (2023)

Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction
por: Domínguez, Eloy, et al.
Publicado: (2018)

Renal function dynamics following co‐administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes
por: de la Espriella, Rafael, et al.
Publicado: (2020)

Heart Failure with Preserved Ejection Fraction: An Urgent Need for Precision Medicine
por: Miñana, Gema, et al.
Publicado: (2021)

Risk of death associated with incident heart failure in patients with known or suspected chronic coronary syndrome
por: Núñez, Julio, et al.
Publicado: (2022)

Beta‐blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve‐HR trial)
por: Palau, Patricia, et al.
Publicado: (2020)

The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations
por: Núñez, Julio, et al.
Publicado: (2021)

Refractory congestive heart failure: when the solution is outside the heart
por: Pernias, Vicente, et al.
Publicado: (2019)

Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Intrarenal venous flow in cardiorenal syndrome: a shining light into the darkness
por: de la Espriella‐Juan, Rafael, et al.
Publicado: (2018)

Efficacy and Safety of Subcutaneous Infusion of Non-formulated Furosemide in Patients with Worsening Heart Failure: a Real-World Study
por: Civera, Jose, et al.
Publicado: (2021)

Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study
por: Miñana, Gema, et al.
Publicado: (2020)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Short‐term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial‐IRON trial
por: Santas, Enrique, et al.
Publicado: (2020)

Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure
por: Bayes-Genis, Antoni, et al.
Publicado: (2016)

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
por: Codina, Pau, et al.
Publicado: (2022)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021)

Validity of the Seattle Heart Failure Model after heart failure hospitalization
por: Li, Song, et al.
Publicado: (2019)

Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO(2) study
por: Mora-Fernández, Carmen, et al.
Publicado: (2023)

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
por: Bayes-Genis, Antoni, et al.
Publicado: (2021)

Coronary Revascularization and Long-Term Survivorship in Chronic Coronary Syndrome
por: Gabaldon-Perez, Ana, et al.
Publicado: (2021)

Peritoneal and Urinary Sodium Removal in Refractory Congestive Heart Failure Patients Included in an Ambulatory Peritoneal Dialysis Program: Valuable for Monitoring the Course of the Disease
por: Miñana, Gema, et al.
Publicado: (2023)

Sex differences on peak oxygen uptake in heart failure
por: Palau, Patricia, et al.
Publicado: (2019)

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction
por: Gastelurrutia, Paloma, et al.
Publicado: (2018)

Heart Failure Treatment by Device
por: Bayés-Genis, Antoni
Publicado: (2020)

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
por: Iborra-Egea, Oriol, et al.
Publicado: (2019)

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial‐IRON Trial
por: Núñez, Julio, et al.
Publicado: (2020)

Optimization of Patient Pathway in Heart Failure with Reduced Ejection Fraction and Worsening Heart Failure. Role of Vericiguat
por: González-Juanatey, José Ramón, et al.
Publicado: (2023)

Management of heart failure with preserved ejection fraction: from neurohormonal antagonists to empagliflozin
por: Aimo, Alberto, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_iq7qa3h4f0sufev57ti3j0h9iv